Analysis Moleculin Biotech, Inc. (0K2H)
5/31/2024
Analysis of Moleculin Biotech, Inc. (0K2H)
Moleculin Biotech, Inc. is a biopharmaceutical company that focuses on the development of oncology drug candidates. Looking at the recent data for stock symbol 0K2H, we can see that the price has been fluctuating around the $5 mark in May 2024.Key indicators such as the Relative Strength Index (RSI), Moving Average Convergence Divergence (MACD), and Moving Averages (MA) provide insights into the stock's performance. The RSI values indicate that the stock has been hovering around the neutral zone, showing neither overbought nor oversold conditions. The MACD values suggest a slight bearish trend, with the MACD line below the signal line.
Overall, the stock seems to be trading in a relatively stable range with some bearish signals in the short term. Investors may want to monitor how the stock performs in the coming days to make informed decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average EPS is projected to be $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, analysts forecast an average EPS of $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates indicate a positive outlook for the company's earnings per share, showing growth and improvement in the upcoming quarters and years.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's quarter. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates increases to 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the analysts are forecasting moderate to strong sales growth for both the upcoming quarters and the next fiscal year, with an increasing number of analysts providing estimates for the company's performance.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
From these estimates, we can see that the company is expected to experience a significant increase in growth compared to the past 5 years, with a particularly strong growth rate projected for the next 5 years. It appears that analysts are optimistic about the company's future performance.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast of $200. The current price is slightly below the average forecast, indicating a potential upside according to the analysts' predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at this time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.Financials:
- Cash flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit margin: 26.306%
- Fiscal year ends: September 30, 2023
- Income statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.43, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating margin: 30.743%
- Most recent quarter: March 31, 2024
- Return on assets TTM: 22.073999%
- Return on equity TTM: 147.25%
Stock statistics:
- Short ratio: 1.53
- Float shares: 15,308,320,742
- Shares short: 99,287,450
- Average 10-day volume: 46,860,048
- Average 90-day volume: 57,498,254
- Shares outstanding: 15,334,099,968
- Percent held by insiders: 5.22%
- Percent held by institutions: 57.589%
- Short percent of shares outstanding: 0.65%
Valuations metrics:
- PEG ratio: 26.319502
- Forward PE: 26.319502
- Trailing PE: 29.59409
- Enterprise value: $2,950,762,332,160
- Price to book MRQ: 39.3405
- Price to sales TTM: 7.646095
- Enterprise to EBITDA: 22.763
- Enterprise to revenue: 7.732
- Market capitalization: $2,917,925,650,432
Stock price summary:
- Beta: 1.264
- 50-day moving average: $176.2646
- 200-day moving average: $181.0429
- Fifty-two week low: $164.08
- Fifty-two week high: $199.62
- Fifty-two week change: 6.853%
Dividends and splits:
- Payout ratio: 14.93%
- Dividend date: May 16, 2024
- Last split date: August 31, 2020
- Ex-dividend date: May 10, 2024
- Last split factor: 4-for-1 split
- Forward annual dividend rate: $1
- 5-year average dividend yield: 0.73%
- Forward annual dividend yield: 0.5255%
- Trailing annual dividend rate: $0.97
- Trailing annual dividend yield: 0.5097%
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been increasing over the years, from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA increasing from $81 billion in 2020 to $129.2 billion in 2023.
7. Despite an increase in income tax expenses, the company has managed to grow its net income continuously.
8. The company has been able to control its operating expenses effectively, allowing for growth in operating income.
9. Non-operating interest expenses have been relatively stable over the years.
10. The number of basic and diluted shares outstanding has remained constant, indicating no significant dilution of shares.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, long-term debt issuance, and payments, with significant fluctuations in values.
6. Investing activities indicate a mix of acquisitions, investments, and capital expenditures, with varying levels of cash flow.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.
MACD of 0K2H
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
